Summary of opinion: Suvaxyn PRRS MLV, 12/02/2026 Positive

Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 10-12 February 2026

Summary of opinion: Bluevac BTV (previously Bluevac BTV8), 12/02/2026 Positive

Concept paper for the revision of the guideline on veterinary good pharmacovigilance practices (VGVP) Module: Signal Management (EMA/522332/2021)

Highlights - 6th EMA-AESGP bilateral meeting

Medicinal products for human use: monthly figures - January 2026

Human medicines European public assessment report (EPAR): Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris, emtricitabine,rilpivirine,tenofovir alafenamide, Date of authorisation: 19/08/2025, Status: Authorised

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 9 - 12 February 2026

Referral: Levamisole-containing medicinal products, levamisole, associated names: Decaris,Levamisol Arena Article 31 referrals Recommendation provided by Pharmacovigilance Risk Assessment Committee, 13/02/2026

EMA recommends withdrawal of marketing authorisations for levamisole medicines